Sudarshan Hebbar
Directeur Technique/Scientifique/R&D chez CALCIMEDICA, INC.
Fortune : 243 340 $ au 30/04/2024
Profil
Sudarshan Hebbar is currently the Chief Medical Officer at CalciMedica, Inc. He previously worked as the Medical Director at Reata Pharmaceuticals, Inc. from 2011 to 2012, and as the Director & Vice President-Medical at Oncimmune Holdings Plc in 2013.
Sudarshan also served as the Senior Medical Director at Abbott Laboratories from 2007 to 2011.
He held the position of Vice President-Nephrology at Thrasos Therapeutics, Inc. and was a Partner at Kidney Associates of Kansas City PC from 1995 to 2007.
Sudarshan completed his undergraduate degree at The Johns Hopkins University and his graduate degree at Tulane University School of Medicine.
Détentions connues dans des sociétés publiques
| Société | Date | Nombre d'actions | Valorisation | Date de valorisation |
|---|---|---|---|---|
CALCIMEDICA, INC.
0,43% | 28/03/2024 | 46 000 ( 0,43% ) | 243 340 $ | 30/04/2024 |
Postes actifs de Sudarshan Hebbar
| Sociétés | Poste | Début |
|---|---|---|
| CALCIMEDICA, INC. | Directeur Technique/Scientifique/R&D | 01/04/2017 |
Anciens postes connus de Sudarshan Hebbar
| Sociétés | Poste | Fin |
|---|---|---|
| ONCIMMUNE HOLDINGS PLC | Directeur/Membre du Conseil | 01/10/2013 |
| REATA PHARMACEUTICALS, INC. | Corporate Officer/Principal | 01/12/2012 |
| ABBOTT LABORATORIES | Corporate Officer/Principal | 01/07/2011 |
| Kidney Associates of Kansas City PC | Corporate Officer/Principal | 01/01/2007 |
Formation de Sudarshan Hebbar
| The Johns Hopkins University | Undergraduate Degree |
| Tulane University School of Medicine | Graduate Degree |
Expériences
Fonctions occupées
Relations
Relations au 1er degré
Entreprises liées au 1er degré
Homme
Femme
Administrateurs
Exécutifs
Sociétés liées
| Sociétés cotées | 3 |
|---|---|
| ABBOTT LABORATORIES | Health Technology |
| ONCIMMUNE HOLDINGS PLC | Health Technology |
| CALCIMEDICA, INC. | Health Technology |
| Entreprise privées | 3 |
|---|---|
Reata Pharmaceuticals, Inc.
 Reata Pharmaceuticals, Inc. Pharmaceuticals: MajorHealth Technology Reata Pharmaceuticals, Inc. is a clinical stage biopharmaceutical company, which engages in identifying, developing, and commercializing pharmaceutical products. Its product candidates are bardoxolone methyl and omaveloxolone, which activate the transcription factor Nrf2 to restore mitochondrial function, reduce oxidative stress, and resolve inflammation. The company was founded by J. Warren Huff in 2002 and is headquartered in Plano, TX. | Health Technology |
Thrasos Therapeutics, Inc.
 Thrasos Therapeutics, Inc. Pharmaceuticals: MajorHealth Technology Thrasos Therapeutics, Inc. operates as a clinical-stage biotherapeutics company which focuses on bringing new solutions to kidney disease patients. It develops novel approaches to protect, treat and restore kidney function for this underserved patient group. The firms products include THR-184 to prevent AKI associated with cardiac surgery, THR-204 to treat certain forms of CKD, and the THR-800 series to treat cast nephropathy, a form of AKI associated with multiple myeloma. The company was founded by William D. Carlson and Murty Bosukonda in 2003 and is headquartered in Montreal, Canada. | Health Technology |
| Kidney Associates of Kansas City PC |